Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

被引：37
|
作者：
Isakoff, Steven J. [1 ]
Baselga, Jose [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; PERTUZUMAB; LAPATINIB; EFFICACY; THERAPY; COMPLEX;
D O I：
10.1200/JCO.2010.31.6679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [31] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Wolff, Antonio C.
    Tung, Nadine M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
  • [32] MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future
    Jhaveri, Komal
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 127 - +
  • [33] PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Cescon, David W.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1318 - +
  • [34] Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer
    Hayashi, Mitsuhiro
    Okumura, Yasuhiro
    Osako, Tomofumi
    Toyozumi, Yasuo
    Arima, Nobuyuki
    Iwase, Hirotaka
    Nishimura, Reiki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (06) : 694 - 700
  • [35] Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
    Perez, Edith A.
    Barrios, Carlos
    Eiermann, Wolfgang
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pierfranco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Burris, Howard A., III
    Petersen, Jennifer A.
    De Haas, Sanne
    Hoersch, Silke
    Patre, Monika
    Ellis, Paul Anthony
    CANCER, 2019, 125 (22) : 3974 - 3984
  • [36] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
    Baselga, Jose
    Gelmon, Karen A.
    Verma, Shailendra
    Wardley, Andrew
    Conte, PierFranco
    Miles, David
    Bianchi, Giulia
    Cortes, Javier
    McNally, Virginia A.
    Ross, Graham A.
    Fumoleau, Pierre
    Gianni, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1138 - 1144
  • [37] Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (06) : 1268 - 1274
  • [38] A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer
    Zoe Kemp
    Alison Jones
    Advances in Therapy, 2011, 28 : 603 - 614
  • [39] Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
    van Mackelenbergh, Marion
    Loibl, Sibylle
    Untch, Michael
    Buyse, Marc
    Geyer, Charles E., Jr.
    Gianni, Luca
    Schneeweiss, Andreas
    Conte, Pierfranco
    Piccart, Martine
    Bonnefoi, Herve
    Jackisch, Christian
    Nekljudova, Valentina
    Tang, Gong
    Valagussa, Pinuccia
    Neate, Colin
    Gelber, Richard
    Poncet, Coralie
    Squifflet, Pierre
    Saad, Everardo D.
    Heinzmann, Dominik
    Denkert, Carsten
    Rastogi, Priya
    Cortes, Javier
    Guarneri, Valentina
    de Azambuja, Evandro
    Cameron, David
    Ismael, Gustavo
    Wolmark, Norman
    Cortazar, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2998 - 3008
  • [40] Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
    Xie, Xiao-Feng
    Zhang, Qiu-Yi
    Huang, Jia-Yi
    Chen, Li-Ping
    Lan, Xiao-Feng
    Bai, Xue
    Song, Lin
    Xiong, Shui-Ling
    Guo, Si-Jia
    Du, Cai-Wen
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 93 - 101
12345